Cullinan Therapeutics, Inc.CGEMNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +36.89% | +36.95% | +7.20% | +1.16% | +1.06% |
| Weighted Average Shares Diluted Growth | +36.89% | +36.95% | +7.20% | +1.16% | +1.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +28.43% | +28.98% | -23.62% | -25.89% | -27.89% |
| Book Value per Share Growth | -4.95% | -5.34% | -30.04% | -28.94% | -31.49% |
| Debt Growth | -40.08% | -41.94% | -44.44% | -51.43% | +24.73% |
| R&D Expense Growth | +16.20% | +35.28% | +68.32% | +18.20% | +6.06% |
| SG&A Expenses Growth | +37.84% | +10.35% | +7.87% | +2.08% | -15.40% |